Robotics firm Fourier bags “tens of thousands of RMB” in Series B round



China-based Shanghai Fourier Intelligence Co., Ltd, which develops exoskeleton robotic products for rehabilitation and orthoses, reportedly raised "tens of thousands of renminbi" via a Series B financing round. The round was led by Shenzhou Guozhong Venture Capital Management Co., Ltd, with IDG Capital and Volcanics Venture also participating. The proceeds will go towards rehabilitative robot R&D, product pipeline expansion, and channel infrastructure.

Fourier’s product lineup includes the Fourier M2, an upper limb rehabilitation robot that was launched as a world-first product in China in December 2016 and the US in March 2018; and the Fourier X1 product, a robotic exoskeleton wearable on the lower limbs to aid walking in patients who have suffered stroke or spinal injury, which launched in March 2017 as reported by GBI. The firm supplies a network of 500 hospitals and rehabilitation care centers in over 10 countries, while forming R&D partnerships with academic institutions in the US, Australia, and UK.

Reference:

Related news
Denmark-based diabetes specialist Novo Nordisk has invested MXN 400 million (USD 21 million) in clinical research in Mexico between 2014 and 2018, involving 1,200 patients in 21 trials.
China-based medical isotopes provider Chengdu New Radiomedicine Technology Co., Ltd, reportedly raised RMB 116 million (USD 16.87 million) in a Series B financing round.
China-based biotechs listing to the Stock Exchange of Hong Kong (HKEX) currently occupy 5 of the global top-10 largest biotech initial public offerings (IPOs) held during the first six months of 2019.
China’s Jiangsu Hengrui Medicine Co., Ltd (600276SH)and its device unit Shanghai Hongchuang Medical Technology Co., Ltd are set to stump up USD 1.2 million and USD 2.8 million respectively to acquire a total 31% stake in US-based Princeps Therapeutics Inc., according to Shanghai Pudong New Area Government’s website.
A report from the Financial Times reveals the impact of US regulatory oversight on venture capital (VC) flows from China into the US.
Recent news
The Brazil-based Institute of Technology and Pharmaceuticals (Farmanguinhos), the drug making unit of the Oswaldo Cruz Foundation (Fiocruz), has delivered its pilot batches of hyperprolactinemia (HPRL) treatment cabergoline, the result of a Productive Development Partnership (PDP) with compatriot laboratory Cristália that concluded this year.
Brazil’s National Health Surveillance Agency (ANVISA) this week granted registration approval to Eli Lilly’s biologic drug Emgality (galcanezumab-gnlm), as revealed by GBI analysis.
The new Science and Technology Innovation Board (STAR) hosted by the Shanghai Stock Exchange (SSE) opened for business on July 22.
Belgium-based UCB announced the market approval in China for Cimzia (certolizumab pegol), for the indication of moderate-to-severe rheumatoid arthritis (RA).
  • 1563867876525
  • China
  • Drug
Denmark-based diabetes specialist Novo Nordisk has invested MXN 400 million (USD 21 million) in clinical research in Mexico between 2014 and 2018, involving 1,200 patients in 21 trials.
The Shandong Centralized Drug Procurement platform released a notification in relation to public hospital drug and consumables procurement alliances.
The “4+7” volume-linked drug procurement pilot scheme introduced at the end of 2018 in 11 cities is set to be expanded to all regions of the country, following a meeting between the National Health Security Administration (NHSA) and industry stakeholders held last week.
  • 1563857070043
  • China
Analytics Snapshot


Analytics Snapshot